According to the new market research report “Aptamers Market by Product Type (DNA, RNA, XNA), Technology (SELEX), Application (Therapeutics, Diagnostics, R&D), End Users (Pharmaceutical & Biotechnology Companies, Academic & Government Research Institutes, CROs) – Global Forecast to 2026″, published by MarketsandMarkets™, is valued at an estimated USD 151 million in 2021 and is projected to reach USD 342 million by 2026, at a CAGR of 17.7% during the forecast period.
Drivers: Rising awareness of the advantages of aptamers over antibodies;
While antibodies have certain limitations in targeting small molecules, aptamers perform better in targeting small molecules. They can bind to small molecules and dyes and thus be easily used in conventional diagnostic kits, extending their use to point-of-care diagnostics. This, in turn, will ensure a greater market value and increase in acceptance of aptamers in addressing both therapeutic and diagnostic applications. Also, aptamers can bind to large molecules. Nearly 98% of the molecules tend to be proteins, making it easier to discover biomarkers and diagnostic kits.
Antibodies are developed by raising an immune response in an animal model or recombinant DNA technology. On the other hand, aptamers can be synthesized using chemical methods which are less costly. Therefore, aptamers are more appealing for the development of new therapeutic drugs and diagnostic kits.
The blood-brain barrier has been a great challenge for antibody-based treatment for neurodegenerative disorders such as Alzheimer’s. Although technological developments have bridged the gap for this challenge, the effectiveness of antibodies against these disorders remains intact. Aptamers are short oligonucleotides that can diffuse across this blood-brain barrier and show potential in treating neurodegenerative disorders.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=1167